Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-10 02:02 UTC

BIOMED PULSE

July 10, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 1,460 confirmed cases and 452 deaths as of July 1, with the PARTNERS clinical trial opening patient enrolment in DRC on July 2 — a historic first attempt to find treatments for this strain. [1] [2]

Mood: Grave on the outbreak front; cautiously hopeful as science mobilizes faster than ever.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) — DRC AND UGANDA

  • As of July 1, 2026, a cumulative 1,460 confirmed cases and 452 deaths have been reported from DRC in the ongoing Bundibugyo virus disease (BVD) outbreak, with cross-border transmission continuing in Uganda. [1]
  • WHO declared this outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, with the IHR Emergency Committee confirming it does not yet meet criteria for a pandemic emergency. [3] [4]
  • Africa CDC and WHO launched a joint continental response plan on June 5, 2026, seeking to raise US$ 518 million to support African countries in preparedness and response. [5]
  • WHO issued its first comprehensive clinical management guidelines for all filovirus diseases, covering Ebola and Marburg, on June 17, 2026. [6]
  • WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2, 2026; the test identifies viral genetic material in blood samples for rapid, accurate confirmation. [7]
  • CDC has been running enhanced Ebola airport screening at Washington-Dulles (from May 21) and Atlanta (from May 23), targeting travelers from affected regions. [8] [9]
  • WHO experts convened on May 28, 2026, to assess candidate vaccines and therapeutics for BVD, as no approved treatments currently exist for the Bundibugyo strain specifically. [10]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The fifth WHO Disease Outbreak News report on the Andes hantavirus (ANDV) cluster linked to cruise ship M/V Hondius was published July 2, 2026; the outbreak was first notified to WHO on May 2, 2026, involving severe acute respiratory illness across passengers from 23 countries.
  • WHO Director-General personally thanked the people of Tenerife, Spain, for safely disembarking and caring for over 120 passengers from 23 countries during the outbreak response operation.
  • CDC's most recent Hantavirus response transcript is from June 24, 2026; risk to the general U.S. public remains described as extremely low.

WEST NILE VIRUS — UNITED STATES

  • CDC reported an early and unusually active West Nile virus season with record case counts ahead of the July 4 holiday weekend, urging Americans to use mosquito repellent and take protective measures.

NIPAH VIRUS — INDIA

  • A laboratory-confirmed case of Nipah virus (NiV) infection was reported in Kozhikode district, Kerala State, India, with symptom onset May 30 and hospitalization June 10, 2026, per WHO's June 25 Disease Outbreak News.
  • Earlier in 2026, two healthcare worker NiV cases were confirmed in West Bengal (notified January 30) and one case in Rajshahi Division, Bangladesh (notified February 6).

MPOX — RECOMBINANT STRAIN, GLOBAL

  • WHO documented cases of a novel recombinant mpox virus combining genomic elements of clade Ib and clade IIb strains in a February 14, 2026, Disease Outbreak News; recombination is a known natural process occurring when two viral strains co-infect the same individual.

E. COLI — FROZEN BLUEBERRIES, UNITED STATES

  • CDC issued a food safety alert on July 7, 2026, warning consumers not to eat recalled frozen blueberries linked to a multistate E. coli outbreak.

MEASLES — BANGLADESH

  • WHO reported a nationwide measles surge in Bangladesh as of April 2026, with 19,161 suspected cases and 2,897 laboratory-confirmed cases across 58 of 64 districts.

YELLOW FEVER — GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission activity in the Americas persisted from a 2025 surge, per WHO's June 24 Disease Outbreak News.

AVIAN INFLUENZA A(H9N2) — ITALY

  • WHO reported one human case of avian influenza A(H9N2) in an adult male returning from Senegal to Italy, confirmed by next-generation sequencing, per the April 10, 2026, Disease Outbreak News.

CANCER — GLOBAL PROJECTION

  • WHO warned on July 8, 2026, that new global cancer cases are projected to nearly double by 2050, with an estimated 20.6 million new cases and close to 10 million deaths already occurring annually.

🧬 LONGEVITY & AGING

NAD+ RESTORATION AND BONE REPAIR IN AGING

  • A new Europe PMC study describes a senescent metabolism-modulating hierarchical scaffold that restores NAD+ homeostasis and redox balance in aged tissues, demonstrating improved bone repair in aged models — targeting a core hallmark of cellular aging.
  • NAD+ is a molecule critical for energy metabolism and DNA repair; its decline with age is linked to accumulating senescent (zombie) cells that impair tissue regeneration.

KAEMPFEROL AND LIFESPAN EXTENSION IN DROSOPHILA

  • Researchers found that kaempferol, a flavonoid compound derived from Moringa oleifera, increased longevity and reduced efavirenz-induced functional senescence in Drosophila melanogaster fruit flies, offering a plant-derived candidate for anti-senescence research.

TAU PROTEIN, NUCLEAR MECHANICS, AND NEURODEGENERATION

  • A July 7, 2026, study in Nucleus journal linked elevated levels of emerin, a mechanically sensitive nuclear membrane protein, to tau-induced cytoskeletal remodeling in neurons — connecting nuclear mechanotransduction to Alzheimer's-associated tau pathology.

INSULIN RESISTANCE AND MILD COGNITIVE IMPAIRMENT

  • A Scandinavian study published June 23, 2026, in Scandinavian Journal of Primary Health Care found associations between insulin resistance and reduced health-related quality of life in people with mild cognitive impairment during aging, reinforcing the metabolic-brain axis as a longevity target.

INFECTION, DELIRIUM, AND DEMENTIA RISK

  • Two linked commentaries in Lancet Healthy Longevity propose delirium following severe infection as a potential missing mechanistic link between acute illness and subsequent dementia — a finding with major implications for post-infection care of older adults.

HYPERTENSION AND FRAILTY

  • A letter published in Blood Pressure journal on July 7, 2026, highlights evidence from the Longitudinal Ageing Study in India connecting hypertension to increased frailty risk among middle-aged and older adults — both highly modifiable longevity risk factors.

MULTIPLE LONG-TERM CONDITIONS AND KIDNEY DISEASE MORTALITY

  • The NURTuRE-CKD multicentre cohort study published June 23, 2026, in Annals of Medicine found that multiple co-existing long-term conditions significantly worsen mortality, progression to kidney failure, and quality of life in people with chronic kidney disease.

LIVER DISEASE AND TOBACCO — GLOBAL BURDEN TO 2038

  • A Europe PMC study published July 3, 2026, modeled the global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) attributable to tobacco from 1990 to 2023 and projected increasing trends through 2038, highlighting tobacco as a modifiable driver of a major aging-related liver condition.

MEDICAL-SOCIAL DETERMINANTS OF HEALTHY LONGEVITY

  • A comprehensive analysis published in Problemy Sotsialnoi Gigieny identified key medical and social determinants of healthy longevity, including healthcare access, lifestyle, and socioeconomic factors, framing a prevention strategy framework for population-level aging outcomes.

💊 NEW CURES & APPROVALS

  • RINVOQ LQ (upadacitinib oral liquid, by AbbVie): Supplemental approval action (SUPPL AP) posted on openFDA for NDA 218347; upadacitinib is a JAK1-selective inhibitor used in inflammatory and autoimmune conditions including rheumatoid arthritis, atopic dermatitis, and ulcerative colitis.
  • BRIMONIDINE TARTRATE AND TIMOLOL MALEATE ophthalmic combination (by Saba Ilac Sanayi): Original approval (ORIG AP) posted on openFDA for ANDA 217934; this fixed-dose combination lowers intraocular pressure in glaucoma and ocular hypertension by dual adrenergic mechanisms.
  • CHLORTHALIDONE (by Macleods Pharma Ltd): Original generic approval (ORIG AP) posted on openFDA for ANDA 212229; chlorthalidone is a thiazide-like diuretic used for hypertension and fluid retention, a leading cardiovascular risk factor in aging populations.
  • LEVOCARNITINE (by Baxter Healthcare Corp): Original approval (ORIG AP) posted on openFDA for ANDA 217896; levocarnitine is used to treat carnitine deficiency, commonly seen in dialysis-dependent kidney disease patients.
  • LEVOTHYROXINE SODIUM (by Fresenius Kabi USA): Supplemental approval (SUPPL AP) posted on openFDA for NDA 202231; used to treat hypothyroidism, highly prevalent in older adults.
  • ACYCLOVIR (by Novitium Pharma): Supplemental approval (SUPPL AP) posted on openFDA for ANDA 212252; acyclovir is an antiviral used against herpes simplex and varicella-zoster viruses.
  • FINASTERIDE supplements by both Teva (ANDA 076511) and Accord Healthcare (ANDA 090121): Supplemental approvals posted on openFDA; finasteride inhibits 5-alpha reductase, used for benign prostatic hyperplasia and androgenetic alopecia.

NOTE: openFDA approval dates are listed as invalid in source data; these reflect the most recently posted approval actions available in the database and should not be interpreted as confirmed July 10, 2026, approval dates.

🧪 CLINICAL TRIALS

BUNDIBUGYO VIRUS DISEASE — FIRST TREATMENT TRIAL

  • The PARTNERS clinical trial opened patient enrolment on July 2, 2026, in DRC, representing the first scientific trial ever to evaluate potential treatments specifically for Ebola Bundibugyo virus disease; this is a major international effort coordinated with WHO support. [2]

HEAT, MICROVASCULAR FUNCTION, AND AGING (NCT06633198)

  • A ClinicalTrials.gov study registered July 9, 2026, is investigating how heat stress affects microvascular (small blood vessel) function across age groups, targeting vascular dysfunction as a shared mechanism underlying multiple chronic age-related diseases.

MIRDAMETINIB PLUS SIROLIMUS FOR RAS-MUTATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (NCT06876142)

  • A trial registered July 9, 2026, is testing the combination of mirdametinib (MEK inhibitor) and sirolimus (mTOR inhibitor) in patients with KRAS or NRAS mutations in relapsed/refractory multiple myeloma — a dual pathway blockade strategy relevant to aging-associated blood cancers.

FOSTAMATINIB IN LUNG TRANSPLANT PATIENTS WITH DONOR-SPECIFIC ANTIBODIES — SIMILAR TRIAL (NCT06948097)

  • The SIMILAR trial, registered July 9, 2026, is evaluating safety and tolerability of fostamatinib, a Syk kinase inhibitor, to mitigate lung allograft rejection driven by donor-specific antibodies in post-transplant patients; median lung transplant survival is currently only 6-7 years.

LMP744 (INDENOISOQUINOLONE CMYC/TOPOISOMERASE 1 INHIBITOR) IN RECURRENT GLIOBLASTOMA (NCT07416188)

  • A Phase I/II trial registered July 9, 2026, is testing LMP744, a novel dual c-MYC and topoisomerase 1 inhibitor, in adults with recurrent glioblastoma, one of the most lethal brain cancers predominantly affecting older adults.

N-803 IL-15 SUPERAGONIST WITH OR WITHOUT ETBX-071 VACCINE IN BIOCHEMICALLY RECURRENT PROSTATE CANCER (NCT07686380)

  • A trial registered July 9, 2026, is testing the IL-15 superagonist N-803 alone or combined with the ETBX-071 vaccine to reduce PSA levels in men with biochemically recurrent prostate cancer after stereotactic body radiation therapy; BCR affects 30,000 to 50,000 men annually.

EMSELLA CHAIR (FOCUSED ELECTROMAGNETIC STIMULATION) FOR MALE SEXUAL DYSFUNCTION (NCT05370651)

  • A two-phase trial registered July 9, 2026, is investigating high-intensity focused electromagnetic (HIFEM) therapy via the Emsella chair versus sham for male sexual dysfunction, beginning with a 10-participant open-label pilot before a sham-controlled phase.

📢 PUBLIC HEALTH

UNSAFE FOOD — GLOBAL BURDEN

  • WHO reported on June 4, 2026, that unsafe food causes 866 million illnesses and 1.5 million deaths globally each year, with children under five facing nearly three times the risk of food-borne illness compared with older individuals.

NICOTINE POUCHES — YOUTH TARGETING

  • WHO warned on May 15, 2026, that nicotine pouch brands are aggressively marketing to youth globally amid surging sales, with at least 40 million children aged 13-15 currently using tobacco products worldwide, and urged governments to impose strong regulatory measures.

CDC TICK BITE SURVEILLANCE — ELEVATED SEASON

  • CDC reported on April 23, 2026, that weekly emergency room visits for tick bites are running higher than usual for this time of year, with Lyme disease and other tickborne illnesses continuing their multi-year geographic expansion across the United States.

WHO PANDEMIC AGREEMENT — PATHOGEN ACCESS ANNEX

  • WHO Director-General issued an open letter to G7, G20, and BRICS leaders on June 15, 2026, urging finalization of the Pathogen Access and Benefit Sharing (PABS) annex of the WHO Pandemic Agreement, describing it as essential unfinished business for global health security.

NEWBORN SCREENING EXPANSION

  • WHO called on June 23, 2026, for countries to expand newborn screening programs for birth defects, citing a new WHO report that early detection and treatment can save lives and reduce lifelong disability in millions of children.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Patient enrolment begins in a scientific trial to identify the… — WHO News
  3. Epidemic of Ebola Disease caused by Bundibugyo virus in the De… — WHO News
  4. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  5. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  6. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  7. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  10. Experts convened by WHO advise on candidate treatments and vac… — WHO News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260710-02-v23 · 2026-07-10 02:02 UTC · pulse.uzylab.com

Read next